IMMUPHARMA PLC — Director's Dealing 2017

Feb 17, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2167X

Immupharma PLC

17 February 2017

	17 FEBRUARY 2017

NOTIFICATION OF INTEREST BY LEGAL & GENERAL

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 3,774,714 million Ordinary Shares in the capital of the Company.

Full disclosure of the TR1 is shown below:

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:			ImmuPharma Plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				Yes
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation:		Legal & General Group Plc (L&G)
4. Full name of shareholder(s) (if different from 3.):		Legal & General Assurance Society Limited (LGAS)
5. Date of the transaction and date on which the threshold is crossed or reached:		15 February 2017
6. Date on which issuer notified:		16 February 2017
7. Threshold(s) that is/are crossed or reached:		L&G (Below 3%)

8. Notified details:
A: Voting rights attached to shares
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares		Number of voting rights			% of  voting rights
Direct		Indirect	Direct			Indirect
ORD GBP 0.10	3,774,714						Below 3%		Below 3%		-	Below 3%			-
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date		Exercise/ Conversion Period					Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date		Exercise/ Conversion period			Number of voting rights instrument refers to				% of voting rights
													Nominal			Delta
Total (A+B+C)
Number of voting rights								Percentage of voting rights
Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position)
Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)  ( Below 5% = Total Position)
Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position)
Legal & General Group Plc (Direct) (L&G) ( Below 3%  = LGAS, LGPL & PMC)
Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)	Legal & General Insurance Holdings Limited (Direct) (LGIH)
Legal & General Assurance (Pensions Management) Limited  (PMC)	Legal & General Assurance Society Limited  (LGAS & LGPL)
	Legal & General Pensions Limited (Direct)  (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold

voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  124,638,362

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

-Ends-

For further information please contact:

ImmuPharma plc (www.immupharma.org)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance Rob Rees, Corporate Broking	+44 (0)20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLZDLFFDLFBBBF